Scinai Immunotherapeutics (SCNI) Total Current Liabilities (2017 - 2026)

Scinai Immunotherapeutics (SCNI) has 10 years of Total Current Liabilities data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities changed N/A year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (changed N/A YoY), and the FY2025 full-year result was $1.6 million, down 12.24% from the prior year.
• Total Current Liabilities climbed to $2.7 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $6.7 million in Q2 2022 to a low of $1.4 million in Q3 2024.
• A 5-year average of $2.3 million and a median of $1.8 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities plunged 93.2% in 2022 and advanced 26.79% in 2025, its largest moves.
• Tracing SCNI's Total Current Liabilities over 5 years: stood at $2.3 million in 2022, then fell by 23.87% to $1.8 million in 2023, then advanced by 1.46% to $1.8 million in 2024, then decreased by 12.24% to $1.6 million in 2025, then surged by 69.4% to $2.7 million in 2026.
• Business Quant data shows SCNI's Total Current Liabilities at $2.7 million in Q1 2026, $1.6 million in Q4 2025, and $2.1 million in Q2 2025.